TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Half-life of zopiclone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative blood loss during the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dropout rates
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: VTE incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: elbow spasticity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: improvement of putting the arm through a sleeve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone remodeling markers (PTH, CTX, P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FIO2>0.95
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 24-hour diurnal intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reduction in BBI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle activity enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle tone effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function test scores on the AD Assessment Scale‐Cognitive Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Regional cerebral blood flow (rCBF) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of treatment-emergent adverse effects (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of Acute Otitis Media (AOM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tissue factor pathway inhibitor (TFPI) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-factors IIa and Xa concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aberrant Behavior Checklist Hyperactivity subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biomarkers of vascular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: family and patient functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: social support for families
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: patients' symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of re-hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Modified SF-36 questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean recovery time for normal physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in DAS28‐4(CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure during postoperative recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Sexual activity at year 1
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of wounds requiring autografting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fresh ischemic insults detected by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: transient neurologic deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: intraocular pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: increase in SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete wound closure by 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chlamydia testing prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of NO(x)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of LPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oxidative stress outcomes
Primary endpoint: Panic disorder symptoms and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shift in allergen concentration to reach reaction threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to normal fluid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RSI and RFS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h pH‐metry <4.0 percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pepsin positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VAS incision pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rush Video‐Based Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HVPG (Hepatic Venous Pressure Gradient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: PVF (Portal Venous Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Delivery of planned treatment schedule
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetic parameters (AUC and C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin levels 24 h after CS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: improvement in positive symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete nasotracheal navigability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: de novo development of TAO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extrusion rate of punctal plugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of vitamin D levels < 50 nmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of adequate CCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performer fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: One-year patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mortality rate during the neonatal period
Endpoint domain: Mortality/survival
Primary endpoint: Complete response for emetic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical effectiveness of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost effectiveness of the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MMTT nadir palmitate rate of appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in multifidus muscle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improved ability to draw-in the abdominal wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fewer games missed due to injury
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in diagnosis after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Final appearance as grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidative damage to DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression of telomere-related genes (TERT and WRAP53)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque increase from baseline to 9-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: cost per quality‐adjusted life‐year gained
Endpoint domain: Resource use
Primary endpoint: Need for augmentation with oxytocin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of Caesarean section for failure to progress
Endpoint domain: Adverse events/effects
Primary endpoint: Stuttered speech severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Body mass index z-score (BMIzsc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time of onset of anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total duration of anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accumulated hard-tissue debris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood culture-confirmed typhoid fever
Endpoint domain: Mortality/survival
Primary endpoint: Seroconversion (Vi IgG level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of children categorized as overweight or obese
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily minutes spent in moderate to vigorous physical activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Utility score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: initiation and growth in heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antioxidant enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐24 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAFLD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: VAS score after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BQT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of sensory deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10‐m walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐10h of serum calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24‐hour urinary calcium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute cellular rejection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of circulating Treg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinically significant traumatic stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Interobserver agreement in diagnosing chronic endometritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional Anisotropy (FA) in white matter tracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Survival without liver transplantation
Endpoint domain: Mortality/survival
Primary endpoint: No ascites at three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arthritic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior and rotational laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute CINV incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed CINV incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Residents learned new relevant product information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Residents strongly agreed that counterdetailing was beneficial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residents would recommend counterdetailing presentations to peers
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: serum levels of IL-6, IL-8, TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cTnI and GP-BB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of women with anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of women with ferritin <30 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean log10 plasma HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Eating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ambulation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma acyl-ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC of terbutaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat retention profile of eyelid warming masks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expulsion rate of LNG-IUD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed use of LNG-IUD at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol and LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absolute serum troponin T release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fatty liver grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal trauma
Endpoint domain: Adverse events/effects
Primary endpoint: Decision to delivery interval (DDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bowel frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of free epinephrine excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite outcome of death, stroke, or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Rate of MAP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disability of Arm and Shoulder Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Night pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velocity of blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: index of vascular pulsation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Nasal Inspiratory Flow (PNIF)
Endpoint domain: Physiological/clinical
Primary endpoint: Nasal Inflammation Score (NIS)
Endpoint domain: Physiological/clinical
Primary endpoint: Thrombus extension at 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Post-ERCP pancreatitis (PEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lack of follicular rupture or ovulatory dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: total fat mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal fat mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiographic valvular features improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: UPDRS-m score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic inflammatory profile associated with COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory volume at 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pelvic floor-muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Female sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postprandial rise in blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin sensitivity (HOMA‐IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined GSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-SSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe incomplete stent apposition (ISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remodeling volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analog Scale scores at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faces Pain Scale scores at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of the ventilatory response to carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effectiveness of IPA treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost effectiveness of IPA treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: type and severity of staining during slit-lamp examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to the first exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAZ (Height-for-Age Z-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic stroke occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Hemorrhagic events occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Depression ratings improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean K values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy intake from dietary sources
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Lower systolic and diastolic blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lower heart rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes